{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:42:08Z","timestamp":1792791728349,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key R&D Program of China","award":["2018YFC0910700"],"award-info":[{"award-number":["2018YFC0910700"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772494"],"award-info":[{"award-number":["81772494"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"crossref","award":["7192036"],"award-info":[{"award-number":["7192036"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010229","name":"Natural Science Foundation of Tianjin Municipal Science and Technology Commission","doi-asserted-by":"crossref","award":["Z161100000516063"],"award-info":[{"award-number":["Z161100000516063"]}],"id":[{"id":"10.13039\/501100010229","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Special Fund of Beijing Municipal Administration of Hospitals Clinical Medicine Development","award":["XMLX201841"],"award-info":[{"award-number":["XMLX201841"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Although EGFR tyrosine kinase inhibitors (EGFR-TKIs) are beneficial to lung adenocarcinoma patients with sensitive EGFR mutations, resistance to these inhibitors induces a cancer stem cell (CSC) phenotype. Here, we clarify the function and molecular mechanism of shisa3 as a suppressor that can reverse EGFR-TKI resistance and inhibit CSC properties.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The suppresser genes involved in EGFR-TKI resistance were identified and validated by transcriptome sequencing, quantitative real-time PCR (qRT-PCR) and immunohistochemistry. Biological function analyses, cell half maximal inhibitory concentration <jats:bold>(<\/jats:bold>IC50), self-renewal, and migration and invasion capacities, were detected by CCK8, sphere formation and Transwell assays. Tumorigenesis and therapeutic effects were investigated in nonobese diabetic\/severe combined immunodeficiency (nod-scid) mice. The underlying mechanisms were explored by Western blot and immunoprecipitation analyses.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>We found that low expression of shisa3 was related to EGFR-TKI resistance in lung adenocarcinoma patients. Ectopic overexpression of shisa3 inhibited CSC properties and the cell cycle in the lung adenocarcinoma cells resistant to gefitinib\/osimertinib. In contrast, suppression of shisa3 promoted CSC phenotypes and the cell cycle in the cells sensitive to EGFR-TKIs. For TKI-resistant PC9\/ER tumors in nod-scid mice, overexpressed shisa3 had a significant inhibitory effect. In addition, we verified that shisa3 inhibited EGFR-TKI resistance by interacting with FGFR1\/3 to regulate AKT\/mTOR signaling. Furthermore, combinational administration of inhibitors of FGFR\/AKT\/mTOR and cell cycle signaling could overcome EGFR-TKI resistance associated with shisa3-mediated CSC capacities in vivo.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Taken together, shisa3 was identified as a brake to EGFR-TKI resistance and CSC characteristics, probably through the FGFR\/AKT\/mTOR and cell cycle pathways, indicating that shisa3 and concomitant inhibition of its regulated signaling may be a promising therapeutic strategy for reversing EGFR-TKI resistance.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13046-019-1486-3","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T20:03:03Z","timestamp":1575489783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties"],"prefix":"10.1186","volume":"38","author":[{"given":"Jiahui","family":"Si","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Wang","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaolei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"key":"1486_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","volume":"28","author":"D Jackman","year":"2010","unstructured":"Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Janne PA, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28:357\u201360.","journal-title":"J Clin Oncol"},{"key":"1486_CR2","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/imm.12866","volume":"153","author":"AS Codd","year":"2018","unstructured":"Codd AS, Kanaseki T, Torigo T, Tabi Z. Cancer stem cells as targets for immunotherapy. Immunology. 2018;153:304\u201314.","journal-title":"Immunology."},{"key":"1486_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.canlet.2016.01.012","volume":"372","author":"L MacDonagh","year":"2016","unstructured":"MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O'Byrne KJ, et al. Lung cancer stem cells: the root of resistance. Cancer Lett. 2016;372:147\u201356.","journal-title":"Cancer Lett"},{"key":"1486_CR4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nm.4409","volume":"23","author":"E Batlle","year":"2017","unstructured":"Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23:1124\u201334.","journal-title":"Nat Med"},{"key":"1486_CR5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/13543776.2017.1325465","volume":"27","author":"PS Kharkar","year":"2017","unstructured":"Kharkar PS. Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015). Expert Opin Ther Pat. 2017;27:753\u201361.","journal-title":"Expert Opin Ther Pat"},{"key":"1486_CR6","doi-asserted-by":"publisher","first-page":"E2526","DOI":"10.1073\/pnas.1522612113","volume":"113","author":"CF Chiu","year":"2016","unstructured":"Chiu CF, Chang YW, Kuo KT, Shen YS, Liu CY, Yu YH, et al. NF-kappaB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance. Proc Natl Acad Sci U S A. 2016;113:E2526\u201335.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1486_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cell.2004.11.051","volume":"120","author":"A Yamamoto","year":"2005","unstructured":"Yamamoto A, Nagano T, Takehara S, Hibi M, Aizawa S. Shisa promotes head formation through the inhibition of receptor protein maturation for the caudalizing factors, Wnt and FGF. Cell. 2005;120:223\u201335.","journal-title":"Cell"},{"issue":"39","key":"1486_CR8","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1038\/s41388-018-0311-3","volume":"37","author":"Kaixuan Wang","year":"2018","unstructured":"Wang K, Ji W, Yu Y, Li Z, Niu X, Xia W, et al. FGFR1-ERK1\/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer. Oncogene. 2018;37:5340\u201354.","journal-title":"Oncogene"},{"key":"1486_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.canlet.2018.02.015","volume":"423","author":"T Lu","year":"2018","unstructured":"Lu T, Li Z, Yang Y, Ji W, Yu Y, Niu X, et al. The hippo\/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer. Cancer Lett. 2018;423:36\u201346.","journal-title":"Cancer Lett"},{"key":"1486_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1164\/rccm.201312-2256OC","volume":"190","author":"CC Chen","year":"2014","unstructured":"Chen CC, Chen HY, Su KY, Hong QS, Yan BS, Chen CH, et al. Shisa3 is associated with prolonged survival through promoting beta-catenin degradation in lung cancer. Am J Respir Crit Care Med. 2014;190:433\u201344.","journal-title":"Am J Respir Crit Care Med"},{"key":"1486_CR11","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","volume":"2","author":"W Pao","year":"2005","unstructured":"Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73.","journal-title":"PLoS Med"},{"key":"1486_CR12","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21:560\u20132.","journal-title":"Nat Med"},{"key":"1486_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12943-018-0793-1","volume":"17","author":"Q Liu","year":"2018","unstructured":"Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018;17:53.","journal-title":"Mol Cancer"},{"key":"1486_CR14","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41467-017-00450-6","volume":"8","author":"K Jacobsen","year":"2017","unstructured":"Jacobsen K, Bertran-Alamillo J, Molina MA, Teixido C, Karachaliou N, Pedersen MH, et al. Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nat Commun. 2017;8:410.","journal-title":"Nat Commun"},{"key":"1486_CR15","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1158\/1078-0432.CCR-17-2961","volume":"24","author":"HA Yu","year":"2018","unstructured":"Yu HA, Suzawa K, Jordan E, Zehir A, Ni A, Kim R, et al. Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance. Clin Cancer Res. 2018;24:3108\u201318.","journal-title":"Clin Cancer Res"},{"key":"1486_CR16","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1164\/rccm.201009-1440OC","volume":"183","author":"TH Chang","year":"2011","unstructured":"Chang TH, Tsai MF, Su KY, Wu SG, Huang CP, Yu SL, et al. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med. 2011;183:1071\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"1486_CR17","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/ijc.29848","volume":"138","author":"K Furugaki","year":"2016","unstructured":"Furugaki K, Fukumura J, Iwai T, Yorozu K, Kurasawa M, Yanagisawa M, et al. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification. Int J Cancer. 2016;138:1024\u201332.","journal-title":"Int J Cancer"},{"key":"1486_CR18","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","volume":"8","author":"Z Piotrowska","year":"2018","unstructured":"Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, et al. Landscape of acquired resistance to Osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with Osimertinib and BLU-667 for acquired RET fusion. Cancer Discov. 2018;8:1529\u201339.","journal-title":"Cancer Discov"},{"key":"1486_CR19","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1158\/0008-5472.CAN-12-4136","volume":"73","author":"K Shien","year":"2013","unstructured":"Shien K, Toyooka S, Yamamoto H, Soh J, Jida M, Thu KL, et al. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 2013;73:3051\u201361.","journal-title":"Cancer Res"},{"key":"1486_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2018.04.022","volume":"427","author":"F Yu","year":"2018","unstructured":"Yu F, Liu JB, Wu ZJ, Xie WT, Zhong XJ, Hou LK, et al. Tumor suppressive microRNA-124a inhibits stemness and enhances gefitinib sensitivity of non-small cell lung cancer cells by targeting ubiquitin-specific protease 14. Cancer Lett. 2018;427:74\u201384.","journal-title":"Cancer Lett"},{"key":"1486_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","volume":"17","author":"SG Wu","year":"2018","unstructured":"Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17:38.","journal-title":"Mol Cancer"},{"key":"1486_CR22","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/1535-7163.MCT-15-1010","volume":"16","author":"J Datta","year":"2017","unstructured":"Datta J, Damodaran S, Parks H, Ocrainiciuc C, Miya J, Yu L, et al. Akt activation mediates acquired resistance to fibroblast growth factor receptor inhibitor BGJ398. Mol Cancer Ther. 2017;16:614\u201324.","journal-title":"Mol Cancer Ther"},{"key":"1486_CR23","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/stem.2787","volume":"36","author":"M Del Re","year":"2018","unstructured":"Del Re M, Arrigoni E, Restante G, Passaro A, Rofi E, Crucitta S, et al. Concise review: resistance to tyrosine kinase inhibitors in non-small cell lung Cancer: the role of Cancer stem cells. Stem Cells. 2018;36:633\u201340.","journal-title":"Stem Cells"},{"key":"1486_CR24","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-09-2943","volume":"16","author":"F Takahashi-Yanaga","year":"2010","unstructured":"Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res. 2010;16:3153\u201362.","journal-title":"Clin Cancer Res"},{"key":"1486_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrclinonc.2010.196","volume":"8","author":"N Takebe","year":"2011","unstructured":"Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, notch, and hedgehog pathways. Nat Rev Clin Oncol. 2011;8:97\u2013106.","journal-title":"Nat Rev Clin Oncol"},{"key":"1486_CR26","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/carcin\/bgx095","volume":"38","author":"O Maehara","year":"2017","unstructured":"Maehara O, Suda G, Natsuizaka M, Ohnishi S, Komatsu Y, Sato F, et al. Fibroblast growth factor-2-mediated FGFR\/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. Carcinogenesis. 2017;38:1073\u201383.","journal-title":"Carcinogenesis."},{"key":"1486_CR27","doi-asserted-by":"publisher","first-page":"16158","DOI":"10.1073\/pnas.0702596104","volume":"104","author":"J Zhou","year":"2007","unstructured":"Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, et al. Activation of the PTEN\/mTOR\/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A. 2007;104:16158\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1486_CR28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3892\/ijmm.2015.2441","volume":"37","author":"Y Lai","year":"2016","unstructured":"Lai Y, Yu X, Lin X, He S. Inhibition of mTOR sensitizes breast cancer stem cells to radiation-induced repression of self-renewal through the regulation of MnSOD and Akt. Int J Mol Med. 2016;37:369\u201377.","journal-title":"Int J Mol Med"},{"key":"1486_CR29","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1038\/onc.2013.310","volume":"33","author":"X Qian","year":"2014","unstructured":"Qian X, Anzovino A, Kim S, Suyama K, Yao J, Hulit J, et al. N-cadherin\/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem\/progenitor cell-like properties. Oncogene. 2014;33:3411\u201321.","journal-title":"Oncogene."},{"key":"1486_CR30","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1158\/0008-5472.CAN-16-2356","volume":"77","author":"R Li","year":"2017","unstructured":"Li R, Ding C, Zhang J, Xie M, Park D, Ding Y, et al. Modulation of Bax and mTOR for Cancer therapeutics. Cancer Res. 2017;77:3001\u201312.","journal-title":"Cancer Res"},{"key":"1486_CR31","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1158\/1535-7163.MCT-15-0029","volume":"14","author":"BW Chen","year":"2015","unstructured":"Chen BW, Chen W, Liang H, Liu H, Liang C, Zhi X, et al. Inhibition of mTORC2 induces cell-cycle arrest and enhances the cytotoxicity of doxorubicin by suppressing MDR1 expression in HCC cells. Mol Cancer Ther. 2015;14:1805\u201315.","journal-title":"Mol Cancer Ther"},{"key":"1486_CR32","doi-asserted-by":"publisher","first-page":"13897","DOI":"10.1038\/ncomms13897","volume":"8","author":"J Zhou","year":"2017","unstructured":"Zhou J, Wu Z, Wong G, Pectasides E, Nagaraja A, Stachler M, et al. CDK4\/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. Nat Commun. 2017;8:13897.","journal-title":"Nat Commun"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1486-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-019-1486-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1486-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T02:13:38Z","timestamp":1606961618000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-019-1486-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1486"],"URL":"https:\/\/doi.org\/10.1186\/s13046-019-1486-3","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"30 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research was approved by the Ethics Committee of Peking University Cancer Hospital. All animal studies were performed in accordance with the animal experimental guidelines of Peking University Cancer Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interest exists.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"481"}}